Methane

Methane

SCHEMBL728022

C.O=C(C=Cc1ccccc1O)c1ccccc1

nearest known ligand 0.73

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.73
MAPK1 P28482 1/20 0.73
TYR P14679 1/20 0.68
NFKB1 P19838 3/20 0.67
CA1 P00915 1/20 0.67
CA2 P00918 1/20 0.67
CA4 P22748 1/20 0.67
BCHE P06276 3/20 0.66
GUSB P08236 1/20 0.66
JUN P05412 1/20 0.63
NFE2L2 Q16236 1/20 0.63
CHRNA7 P36544 3/20 0.60
LMNA P02545 3/20 0.59
RAB9A P51151 2/20 0.58
NPC1 O15118 1/20 0.58
MAOB P27338 2/20 0.58
PLIN1 O60240 1/20 0.58
TNFRSF1A P19438 1/20 0.58
ACHE P22303 1/20 0.58
RECQL P46063 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10893208 0.98 MAPT (0.75) MAPTMAPK1TYRNFKB1CA1
SCHEMBL626785 0.98 MAPT (0.75) MAPTMAPK1TYRNFKB1CA1
SCHEMBL626787 0.98 MAPT (0.75) MAPTMAPK1TYRNFKB1CA1
SCHEMBL29420130 0.98 MAPT (0.75) MAPTMAPK1TYRNFKB1CA1
Chalcone SCHEMBL28301237 0.91 CYP1B1 (0.73) MAPTMAPK1TYRNFKB1CA1
SCHEMBL21647113 0.88 MAPT (0.71) MAPTMAPK1TYRNFKB1CA1
SCHEMBL9250766 0.87 MAPT (0.76) MAPTMAPK1TYRNFKB1CA1
SCHEMBL5576960 0.87 MAPT (0.76) MAPTMAPK1TYRNFKB1CA1
SCHEMBL9006476 0.86 MAPT (0.69) MAPTMAPK1TYRNFKB1BCHE
SCHEMBL1073514 0.86 IAPP (0.62) MAPTMAPK1TYRNFKB1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104705565-A Method for preparing three-high (high blood lipid, high blood pressure and high blood sugar) prevention dietary therapy rice WANG YUEJIN 2015-06-17 CN claimed
EP-1534314-B1 A nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction DSM IP ASSETS BV (NL) 2014-10-22 EP claimed
JP-4719465-B2 2011-07-06 JP claimed
US-7648957-B2 Nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction DSM IP ASSETS B.V. (NL) 2010-01-19 US claimed
JP-2006502154-A 2006-01-19 JP claimed
US-20050271744-A1 Nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction DSM IP ASSETS B.V. (NL) 2005-12-08 US claimed
US-6903136-B2 Food supplements containing 4-hydroxyisoleucine and creatine EXPERIMENTAL AND APPLIED SCIENCES, INC. (US) 2005-06-07 US claimed
EP-1534314-A1 A NUTRITIONAL AND THERAPEUTIC COMPOSITION OF AN INSULIN SENSITIZER AND A PEPTIDE FRACTION DSM IP Assets B.V. (NL) 2005-06-01 EP claimed
WO-2004022083-A1 A NUTRITIONAL AND THERAPEUTIC COMPOSITION OF AN INSULIN SENSITIZER AND A PEPTIDE FRACTION DSM IP ASSETS B.V. (NL) 2004-03-18 WO claimed
US-20030224062-A1 Food supplements containing 4-hydroxyisoleucine and creatine NATIONAL SUPPLEMENT ASSOCIATION, INCORPORATED 2003-12-04 US claimed
WO-2003088947-A1 FOOD SUPPLEMENTS CONTAINING 4-HYDROXYISOLEUCINE AND CREATINE EXPERIMENTAL & APPLIED SCIENCES, INC. (US) 2003-10-30 WO claimed
US-20200179308-A1 USE OF ISOHUMULONES AND DERIVATIVES THEREOF TO TREAT POLYCYSTIC OVARY SYNDROME KINDEX PHARMACEUTICALS, INC. 2020-06-11 US disclosed
EP-3609862-A1 USE OF ISOHUMULONES AND DERIVATIVES THEREOF TO TREAT POLYCYSTIC OVARY SYNDROME Kindex Pharmaceuticals, Inc. (US) 2020-02-19 EP disclosed
EP-3107556-B1 COMPOSITIONS FOR PREVENTING AND/OR TREATING PATHOLOGICAL CONDITIONS ASSOCIATED WITH ALPHA-GLUCOSIDASE UNIV LA ROCHELLE (FR) 2019-04-10 EP disclosed
WO-2018191522-A1 USE OF ISOHUMULONES AND DERIVATIVES THEREOF TO TREAT POLYCYSTIC OVARY SYNDROME KINDEX THERAPEUTICS, LLC (US) 2018-10-18 WO disclosed
US-6787163-B2 Therapeutic treatment for blood sugar regulation HARRIS DENNIS H (US) 2004-09-07 US disclosed
US-20040142045-A1 THERAPEUTIC TREATMENT FOR BLOOD SUGAR REGULATION HARRIS DENNIS H (US) 2004-07-22 US disclosed
WO-2004022083-A1 A NUTRITIONAL AND THERAPEUTIC COMPOSITION OF AN INSULIN SENSITIZER AND A PEPTIDE FRACTION DSM IP ASSETS B.V. (NL) 2004-03-18 WO disclosed
US-20030224062-A1 Food supplements containing 4-hydroxyisoleucine and creatine NATIONAL SUPPLEMENT ASSOCIATION, INCORPORATED 2003-12-04 US disclosed
WO-2003088947-A1 FOOD SUPPLEMENTS CONTAINING 4-HYDROXYISOLEUCINE AND CREATINE EXPERIMENTAL & APPLIED SCIENCES, INC. (US) 2003-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200179308-A1 USE OF ISOHUMULONES AND DERIVATIVES THEREOF TO TREAT POLYCYSTIC OVARY SYNDROME PKD1, TKT, CPT1A MAPT 2919/4885MAPK1 3497/4885TYR 2633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.